Legend Biotech Corporation (LEGN)

Market Cap	3.61B -39.3%
Revenue (ttm)	1.27B +59.5%
Net Income	-91.50M
EPS	-0.50
Shares Out	193.77M
PE Ratio	n/a
Forward PE	42.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,387,470
Open	18.78
Previous Close	18.71
Day's Range	18.55 - 19.06
52-Week Range	16.24 - 37.50
Beta	0.57
Analysts	Buy
Price Target	46.19 (+148.07%)
Est. Earnings	Nov 11, 2026

About LEGN

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lym...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 2,965
• Stock Exchange: Nasdaq
• Ticker Symbol: LEGN
• Website: https://legendbiotech.com

Financial Performance

In 2025, Legend Biotech's revenue was $1.03 billion, an increase of 64.02% compared to the previous year's $627.30 million. Losses were -$296.80 million, 67.7% more than in 2024.

Analyst Summary

According to 13 analysts, the average rating for LEGN stock is "Buy." The 12-month stock price target is $46.19, which is an increase of 148.07% from the latest price.

Price Target

$46.19

(148.07% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error